First National Trust’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.97M Sell
49,035
-3,066
-6% -$179K 0.1% 152
2025
Q4
$2.81M Sell
52,101
-1,463
-3% -$70.4K 0.09% 159
2025
Q3
$2.42M Buy
53,564
+15,742
+42% +$735K 0.08% 174
2025
Q2
$1.75M Sell
37,822
-2,632
-7% -$129K 0.07% 192
2025
Q1
$2.47M Sell
40,454
-14,756
-27% -$860K 0.1% 159
2024
Q4
$3.12M Sell
55,210
-5,037
-8% -$281K 0.12% 139
2024
Q3
$3.12M Sell
60,247
-6,035
-9% -$283K 0.12% 134
2024
Q2
$2.75M Sell
66,282
-27,057
-29% -$1.21M 0.11% 138
2024
Q1
$5.06M Sell
93,339
-119,168
-56% -$6.07M 0.21% 105
2023
Q4
$10.9M Sell
212,507
-37,295
-15% -$1.96M 0.48% 59
2023
Q3
$14.5M Sell
249,802
-67,816
-21% -$4.16M 0.69% 40
2023
Q2
$20.3M Buy
317,618
+5,381
+2% +$361K 0.94% 25
2023
Q1
$21.6M Buy
312,237
+2,260
+0.7% +$159K 1.15% 18
2022
Q4
$22.3M Buy
309,977
+7,682
+3% +$579K 1.18% 19
2022
Q3
$21.5M Buy
302,295
+5,004
+2% +$363K 1.25% 16
2022
Q2
$22.9M Buy
297,291
+76,202
+34% +$5.8M 1.29% 16
2022
Q1
$16.1M Buy
221,089
+37,709
+21% +$2.53M 0.84% 29
2021
Q4
$11.4M Buy
183,380
+11,361
+7% +$666K 0.6% 49
2021
Q3
$10.2M Buy
172,019
+3,765
+2% +$248K 0.61% 50
2021
Q2
$11.2M Sell
168,254
-3,333
-2% -$217K 0.68% 42
2021
Q1
$10.8M Sell
171,587
-13,379
-7% -$832K 0.71% 38
2020
Q4
$11.5M Buy
184,966
+20,123
+12% +$1.24M 0.79% 36
2020
Q3
$9.94M Buy
164,843
+9,717
+6% +$585K 0.77% 39
2020
Q2
$9.12M Buy
155,126
+10,454
+7% +$625K 0.77% 39
2020
Q1
$8.06M Buy
144,672
+7,418
+5% +$453K 0.81% 39
2019
Q4
$8.81M Buy
137,254
+5,806
+4% +$333K 0.72% 42
2019
Q3
$6.67M Buy
131,448
+7,909
+6% +$372K 0.6% 52
2019
Q2
$5.6M Buy
123,539
+35,549
+40% +$1.66M 0.52% 56
2019
Q1
$4.2M Buy
87,990
+34,902
+66% +$1.74M 0.42% 71
2018
Q4
$2.76M Sell
53,088
-3,740
-7% -$201K 0.31% 95
2018
Q3
$3.53M Sell
56,828
-3,975
-7% -$236K 0.36% 85
2018
Q2
$3.37M Sell
60,803
-2,060
-3% -$111K 0.37% 84
2018
Q1
$3.98M Sell
62,863
-3,113
-5% -$200K 0.45% 68
2017
Q4
$4.04M Sell
65,976
-1,444
-2% -$90.3K 0.44% 67
2017
Q3
$4.3M Sell
67,420
-389
-0.6% -$22.7K 0.5% 56
2017
Q2
$3.78M Buy
67,809
+1,393
+2% +$75.8K 0.46% 61
2017
Q1
$3.61M Sell
66,416
-2,420
-4% -$133K 0.47% 59
2016
Q4
$4.02M Sell
68,836
-5,876
-8% -$321K 0.57% 46
2016
Q3
$4.03M Buy
74,712
+3,521
+5% +$226K 0.61% 46
2016
Q2
$5.24M Sell
71,191
-19,753
-22% -$1.4M 0.8% 34
2016
Q1
$5.81M Sell
90,944
-2,257
-2% -$142K 0.89% 29
2015
Q4
$6.41M Sell
93,201
-3,949
-4% -$261K 1.01% 24
2015
Q3
$5.75M Sell
97,150
-4,365
-4% -$277K 0.99% 26
2015
Q2
$6.75M Sell
101,515
-3,645
-3% -$240K 1.09% 23
2015
Q1
$6.78M Sell
105,160
-10,555
-9% -$661K 1.16% 19
2014
Q4
$6.83M Sell
115,715
-7,733
-6% -$436K 1.22% 17
2014
Q3
$6.32M Sell
123,448
-25,431
-17% -$1.27M 1.2% 18
2014
Q2
$7.22M Buy
148,879
+13,827
+10% +$681K 1.39% 11
2014
Q1
$7.02M Sell
135,052
-1,741
-1% -$92.6K 1.25% 13
2013
Q4
$7.27M Sell
136,793
-7,290
-5% -$371K 1.32% 12
2013
Q3
$6.67M Sell
144,083
-1,952
-1% -$85.7K 1.31% 12
2013
Q2
$6.53M Buy
+146,035
New +$6.34M 1.34% 12

Other funds holding BMY

First National Trust's BMY Position: Q1 2026 in Review

First National Trust reduced its Bristol-Myers Squibb (BMY) stake by 5.9% in Q1 2026, selling an estimated $179K and leaving 49,035 shares worth $2.97M. The position accounts for 0.1% of the portfolio, ranked #152.

First National Trust first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $22.9M in Q2 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • First National Trust held 49,035 shares of Bristol-Myers Squibb worth $2.97M as of Q1 2026.
  • First National Trust sold 3,066 Bristol-Myers Squibb shares in Q1 2026, an estimated $179K.
  • Bristol-Myers Squibb made up 0.1% of First National Trust's portfolio in Q1 2026, its #152 holding.
  • First National Trust first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • First National Trust's Bristol-Myers Squibb position peaked at $22.9M in Q2 2022.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on First National Trust's 13F filing for Q1 2026, filed 7 May 2026.